Photo by nci from unsplash
We read with great interest the results of the recently published Riociguat Safety and Efficacy in Systemic Sclerosis (RISE-SSc) trial1 and believe that additional analyses could further elucidate the role… Click to show full abstract
We read with great interest the results of the recently published Riociguat Safety and Efficacy in Systemic Sclerosis (RISE-SSc) trial1 and believe that additional analyses could further elucidate the role of riociguat in systemic sclerosis (SSc). First, considering the pleiotropic (antifibrotic, anti-inflammatory and antiproliferative) actions of riociguat, an analysis of the radiographic findings [pattern- cellular non-specific interstitial pneumonia (NSIP), fibrotic NSIP or usual interstitial pneumonia (UIP); and …
Journal Title: Annals of the rheumatic diseases
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!